• Zimmer Biomet Holdings recently highlighted its musculoskeletal portfolio and ROSA robotic-assisted surgery platform at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 in Miami, underscoring its focus on advanced orthopedic solutions.
• The company’s push into cementless implants, robotics, and faster-growing areas like upper extremities and foot and ankle care is reinforcing its positioning in orthopedic innovation despite questions about long-term joint replacement demand.
• We’ll now examine how Zimmer Biomet’s expanding ROSA robotic-assisted surgery platform shapes the company’s broader investment narrative for investors.

Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is Zimmer Biomet Holdings' Investment Narrative?

For Zimmer Biomet, the big-picture belief is that orthopedic demand, robotics and digital tools can together support a durable, if unspectacular, earnings story, even as headline concerns swirl around GLP‑1 weight loss drugs and long-term joint replacement volumes. The recent Goldman Sachs conference appearance fits neatly into this, reinforcing management’s emphasis on the ROSA platform, cementless implants and expansion into upper extremities, foot and ankle, and craniomaxillofacial segments, but it is unlikely to change near-term catalysts in a material way. Short-term, the more tangible drivers remain execution against modest 2026 revenue guidance, margin progress after a period of compressed profitability, and ongoing buybacks under the US$1.5 billion authorization. Key risks continue to center on high debt levels, mixed earnings quality and any evidence that GLP‑1 adoption is starting to affect procedure volumes.

However, one emerging risk could quietly reshape expectations around future joint replacement demand. Zimmer Biomet Holdings' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Explore 4 other fair value estimates on Zimmer Biomet Holdings - why the stock might be worth just $98.70!

Form Your Own Verdict

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Zimmer Biomet Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Zimmer Biomet Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zimmer Biomet Holdings' overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.